Search

Your search keyword '"Tur, Carmen"' showing total 527 results
Start Over Author "Tur, Carmen"
527 results on '"Tur, Carmen"'

2. Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial

Author

Bosch-Nicolau, Pau, Fernández, Marisa L, Sulleiro, Elena, Villar, Juan Carlos, Perez-Molina, José A, Correa-Oliveira, Rodrigo, Sosa-Estani, Sergio, Sánchez-Montalvá, Adrián, del Carmen Bangher, Maria, Moreira, Otacilio C, Salvador, Fernando, Mota Ferreira, Ariela, Eloi-Santos, Silvana Maria, Serre-Delcor, Núria, Ramírez, Juan Carlos, Silgado, Aroa, Oliveira, Inés, Martín, Oihane, Aznar, Maria Luisa, Ribeiro, Antonio Luiz P, Almeida, Paulo Emilio Clementino, Chamorro-Tojeiro, Sandra, Espinosa-Pereiro, Juan, de Paula, Alfredo Mauricio Batista, Váquiro-Herrera, Eliana, Tur, Carmen, and Molina, Israel

Published
2024
Full Text
View/download PDF

4. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

Author

Coll, Llucia, Pareto, Deborah, Carbonell-Mirabent, Pere, Cobo-Calvo, Álvaro, Arrambide, Georgina, Vidal-Jordana, Ángela, Comabella, Manuel, Castilló, Joaquín, Rodríguez-Acevedo, Breogán, Zabalza, Ana, Galán, Ingrid, Midaglia, Luciana, Nos, Carlos, Salerno, Annalaura, Auger, Cristina, Alberich, Manel, Río, Jordi, Sastre-Garriga, Jaume, Oliver, Arnau, Montalban, Xavier, Rovira, Àlex, Tintoré, Mar, Lladó, Xavier, and Tur, Carmen

Published
2023
Full Text
View/download PDF

6. Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab

Author

Carvajal, René, primary, Zabalza, Ana, additional, Carbonell-Mirabent, Pere, additional, Martínez-Gómez, Xavier, additional, Esperalba, Juliana, additional, Pappolla, Agustín, additional, Rando, Ariadna, additional, Cobo-Calvo, Alvaro, additional, Tur, Carmen, additional, Rodriguez, Marta, additional, Río, Jordi, additional, Comabella, Manuel, additional, Castilló, Joaquín, additional, Rodrigo-Pendás, José Ángel, additional, Braga, Nathane, additional, Mongay-Ochoa, Neus, additional, Guío-Sánchez, Claudia, additional, Vidal-Jordana, Ángela, additional, Arrambide, Georgina, additional, Rodríguez-Acevedo, Breogán, additional, Midaglia, Luciana, additional, Borras-Bermejo, Blanca, additional, Galán, Ingrid, additional, Sastre-Garriga, Jaume, additional, Montalban, Xavier, additional, Otero-Romero, Susana, additional, and Tintoré, Mar, additional

Published
2024
Full Text
View/download PDF

7. Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Author

Bollo, Luca, primary, Arrambide, Georgina, additional, Cobo-Calvo, Alvaro, additional, Alvarez, Javier V., additional, Alberich, Manel, additional, Cabello, Sergio, additional, Castilló, Joaquín, additional, Galan, Ingrid, additional, Midaglia, Luciana S., additional, Acevedo, Breogan Rodriguez, additional, Zabalza, Ana, additional, Pappolla, Agustin, additional, Mongay Ochoa, Neus, additional, Tintore, Mar, additional, Rio, Jordi, additional, Comabella, Manuel, additional, Tur, Carmen, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, Rovira, Alex, additional, Montalban, Xavier, additional, Pareto, Deborah, additional, and Vidal-Jordana, Angela, additional

Published
2024
Full Text
View/download PDF

8. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

Author

Cobo-Calvo, Alvaro, Zabalza, Ana, Río, Jordi, Arrambide, Georgina, Otero-Romero, Susana, Tagliani, Paula, Cárdenas-Robledo, Simón, Castillo, Mireia, Espejo, Carmen, Rodriguez, Marta, Carbonell, Pere, Rodríguez, Breogán, Midaglia, Luciana, Vidal-Jordana, Ángela, Tur, Carmen, Galan, Ingrid, Castillo, Joaquín, Comabella, Manuel, Nos, Carlos, Auger, Cristina, Tintoré, Mar, Rovira, Àlex, Montalban, Xavier, and Sastre-Garriga, Jaume

Published
2022
Full Text
View/download PDF

9. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Author

Río, Jordi, Rovira, Àlex, Gasperini, Claudio, Tintoré, Mar, Prosperini, Luca, Otero-Romero, Susana, Comabella, Manuel, Vidal-Jordana, Ángela, Galán, Ingrid, Midaglia, Luciana, Rodriguez-Acevedo, Breogán, Zabalza, Ana, Castilló, Joaquim, Arrambide, Georgina, Nos, Carlos, Cobo, Álvaro, Tur, Carmen, Auger, Cristina, Sastre-Garriga, Jaume, and Montalban, Xavier

Published
2022
Full Text
View/download PDF

11. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs

Author

Pappolla, Agustin, primary, Auger, Cristina, additional, Sao-Aviles, Augusto, additional, Tur, Carmen, additional, Rodriguez-Barranco, Marta, additional, Cobo-Calvo, Álvaro, additional, Mongay-Ochoa, Neus, additional, Rodríguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Midaglia, Luciana, additional, Carbonell-Mirabent, Pere, additional, Carvajal, Rene, additional, Castilló-Justribó, Joaquín, additional, Braga, Nathane, additional, Bollo, Luca, additional, Vidal-Jordana, Angela, additional, Arrambide, Georgina, additional, Nos, Carlos, additional, Salerno, Annalaura, additional, Galán, Ingrid, additional, Comabella, Manuel, additional, Sastre-Garriga, Jaume, additional, Tintoré, Mar, additional, Rovira, Alex, additional, Montalban, Xavier, additional, and Río, Jordi, additional

Published
2024
Full Text
View/download PDF

14. Evolution of brain MRI lesions in paediatric myelinoligodendrocyte glycoprotein antibody- associated disease (MOGAD) and its relevance to disease course.

Author

Abdel-mannan, Omar, Champsas, Dimitrios, Tur, Carmen, Lee, Vanessa, Manivannan, Sharmila, Usman, Haroon, Skippen, Alison, Desai, Ishita, Chitre, Manali, Forsyth, Rob, Kneen, Rachel, Ram, Dipak, Ramdas, Sithara, Rossor, Thomas, West, Siobhan, Wright, Sukhvir, Palace, Jacqueline, Wassmer, Evangeline, Hemingway, Cheryl, and J. Lim, Ming

Subjects
NEUROMYELITIS optica, BRAIN damage, DISEASE complications, DISEASE progression, MEDICAL care, POSTVACCINAL encephalitis
Published
2024
Full Text
View/download PDF

15. Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–associated disease.

Author

Bianchi, Alessia, Cortese, Rosa, Prados, Ferran, Tur, Carmen, Kanber, Baris, Yiannakas, Marios C, Samson, Rebecca, De Angelis, Floriana, Magnollay, Lise, Jacob, Anu, Brownlee, Wallace, Trip, Anand, Nicholas, Richard, Hacohen, Yael, Barkhof, Frederik, Ciccarelli, Olga, and Toosy, Ahmed T

Subjects
NEUROMYELITIS optica, MULTIPLE sclerosis, MYELIN oligodendrocyte glycoprotein, AQUAPORINS, MAGNETIZATION transfer, OPTIC neuritis
Abstract

Background: Optic neuritis (ON) is a common feature of inflammatory demyelinating diseases (IDDs) such as multiple sclerosis (MS), aquaporin 4-antibody neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). However, the involvement of the optic chiasm (OC) in IDD has not been fully investigated. Aims: To examine OC differences in non-acute IDD patients with (ON+) and without ON (ON−) using magnetisation transfer ratio (MTR), to compare differences between MS, AQP4 + NMOSD and MOGAD and understand their associations with other neuro-ophthalmological markers. Methods: Twenty-eight relapsing-remitting multiple sclerosis (RRMS), 24 AQP4 + NMOSD, 28 MOGAD patients and 32 healthy controls (HCs) underwent clinical evaluation, MRI and optical coherence tomography (OCT) scan. Multivariable linear regression models were applied. Results: ON + IDD patients showed lower OC MTR than HCs (28.87 ± 4.58 vs 31.65 ± 4.93; p = 0.004). When compared with HCs, lower OC MTR was found in ON + AQP4 + NMOSD (28.55 ± 4.18 vs 31.65 ± 4.93; p = 0.020) and MOGAD (28.73 ± 4.99 vs 31.65 ± 4.93; p = 0.007) and in ON− AQP4 + NMOSD (28.37 ± 7.27 vs 31.65 ± 4.93; p = 0.035). ON+ RRMS had lower MTR than ON− RRMS (28.87 ± 4.58 vs 30.99 ± 4.76; p = 0.038). Lower OC MTR was associated with higher number of ON (regression coefficient (RC) = −1.15, 95% confidence interval (CI) = −1.819 to −0.490, p = 0.001), worse visual acuity (RC = −0.026, 95% CI = −0.041 to −0.011, p = 0.001) and lower peripapillary retinal nerve fibre layer (pRNFL) thickness (RC = 1.129, 95% CI = 0.199 to 2.059, p = 0.018) when considering the whole IDD group. Conclusion: OC microstructural damage indicates prior ON in IDD and is linked to reduced vision and thinner pRNFL. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. What contributes to disability in progressive MS? A brain and cervical cord–matched quantitative MRI study.

Author

Tur, Carmen, Battiston, Marco, Yiannakas, Marios C, Collorone, Sara, Calvi, Alberto, Prados, Ferran, Kanber, Baris, Grussu, Francesco, Ricciardi, Antonio, Pajak, Patrizia, Martinelli, Daniele, Schneider, Torben, Ciccarelli, Olga, Samson, Rebecca S, and Wheeler-Kingshott, Claudia AM Gandini

Abstract

Background: We assessed the ability of a brain-and-cord-matched quantitative magnetic resonance imaging (qMRI) protocol to differentiate patients with progressive multiple sclerosis (PMS) from controls, in terms of normal-appearing (NA) tissue abnormalities, and explain disability. Methods: A total of 27 patients and 16 controls were assessed on the Expanded Disability Status Scale (EDSS), 25-foot timed walk (TWT), 9-hole peg (9HPT) and symbol digit modalities (SDMT) tests. All underwent 3T brain and (C2-C3) cord structural imaging and qMRI (relaxometry, quantitative magnetisation transfer, multi-shell diffusion-weighted imaging), using a fast brain-and-cord–matched protocol with brain-and-cord–unified imaging readouts. Lesion and NA-tissue volumes and qMRI metrics reflecting demyelination and axonal loss were obtained. Random forest analyses identified the most relevant volumetric/qMRI measures to clinical outcomes. Confounder-adjusted linear regression estimated the actual MRI-clinical associations. Results: Several qMRI/volumetric differences between patients and controls were observed (p < 0.01). Higher NA-deep grey matter quantitative-T1 (EDSS: beta = 7.96, p = 0.006; 9HPT: beta = −0.09, p = 0.004), higher NA-white matter orientation dispersion index (TWT: beta = −3.21, p = 0.005; SDMT: beta = −847.10, p < 0.001), lower whole-cord bound pool fraction (9HPT: beta = 0.79, p = 0.001) and higher NA-cortical grey matter quantitative-T1 (SDMT = −94.31, p < 0.001) emerged as particularly relevant predictors of greater disability. Conclusion: Fast brain-and-cord–matched qMRI protocols are feasible and identify demyelination – combined with other mechanisms – as key for disability accumulation in PMS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Spatial Characterisation of Fibre Response Functions for Spherical Deconvolution in Multiple Sclerosis

Author

Tur, Carmen, Grussu, Francesco, Prados, Ferran, Collorone, Sara, Wheeler-Kingshott, Claudia A. M. Gandini, Ciccarelli, Olga, Hege, Hans-Christian, Series Editor, Hoffman, David, Series Editor, Johnson, Christopher R., Series Editor, Polthier, Konrad, Series Editor, Rumpf, Martin, Series Editor, Bonet-Carne, Elisenda, editor, Grussu, Francesco, editor, Ning, Lipeng, editor, Sepehrband, Farshid, editor, and Tax, Chantal M. W., editor

Published
2019
Full Text
View/download PDF

19. Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course

Author

Abdel-mannan, Omar, primary, Champsas, Dimitrios, additional, Tur, Carmen, additional, Lee, Vanessa, additional, Manivannan, Sharmila, additional, Usman, Haroon, additional, Skippen, Alison, additional, Desai, Ishita, additional, Chitre, Manali, additional, Forsyth, Rob, additional, Kneen, Rachel, additional, Ram, Dipak, additional, Ramdas, Sithara, additional, Rossor, Thomas, additional, West, Siobhan, additional, Wright, Sukhvir, additional, Palace, Jacqueline, additional, Wassmer, Evangeline, additional, Hemingway, Cheryl, additional, Lim, Ming J, additional, Mankad, Kshitij, additional, Ciccarelli, Olga, additional, and Hacohen, Yael, additional

Published
2023
Full Text
View/download PDF

20. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis

Author

Calvi, Alberto, primary, Mendelsohn, Zoe, additional, Hamed, Weaam, additional, Chard, Declan, additional, Tur, Carmen, additional, Stutters, Jon, additional, MacManus, David, additional, Kanber, Baris, additional, Wheeler‐Kingshott, Claudia A. M. Gandini, additional, Barkhof, Frederik, additional, and Prados, Ferran, additional

Published
2023
Full Text
View/download PDF

21. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

Author

Zabalza, Ana, Arrambide, Georgina, Tagliani, Paula, Cárdenas-Robledo, Simón, Otero-Romero, Susana, Esperalba, Juliana, Fernandez-Naval, Candela, Trocoli Campuzano, Jesus, Martínez Gallo, Mónica, Castillo, Mireia, Bonastre, Mercè, Resina Sallés, Mireia, Beltran, Jordina, Carbonell-Mirabent, Pere, Rodríguez-Barranco, Marta, López-Maza, Samuel, Melgarejo Otálora, Pedro José, Ruiz-Ortiz, Mariano, Pappolla, Agustin, Rodríguez Acevedo, Breogán, Midaglia, Luciana, Vidal-Jordana, Angela, Cobo-Calvo, Alvaro, Tur, Carmen, Galán, Ingrid, Castilló, Joaquín, Río, Jordi, Espejo, Carmen, Comabella, Manuel, Nos, Carlos, Sastre-Garriga, Jaume, Tintore, Mar, and Montalban, Xavier

Published
2022
Full Text
View/download PDF

22. Longitudinal Analysis Framework of DWI Data for Reconstructing Structural Brain Networks with Application to Multiple Sclerosis

Author

Charalambous, Thalis, Prados, Ferran, Tur, Carmen, Kanber, Baris, Ourselin, Sebastien, Chard, Declan, Clayden, Jonathan D., Wheeler-Kingshott, Claudia A. M., Thompson, Alan, Toosy, Ahmed, Hege, Hans-Christian, Series Editor, Hoffman, David, Series Editor, Johnson, Christopher R., Series Editor, Polthier, Konrad, Series Editor, Rumpf, Martin, Series Editor, Kaden, Enrico, editor, Grussu, Francesco, editor, Ning, Lipeng, editor, Tax, Chantal M. W., editor, and Veraart, Jelle, editor

Published
2018
Full Text
View/download PDF

23. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

Author

Cobo-Calvo, Alvaro, Zabalza, Ana, Río, Jordi, Arrambide, Georgina, Otero-Romero, Susana, Tagliani, Paula, Cárdenas-Robledo, Simón, Castillo, Mireia, Espejo, Carmen, Rodriguez, Marta, Carbonell, Pere, Rodríguez, Breogán, Midaglia, Luciana, Vidal-Jordana, Ángela, Tur, Carmen, Galan, Ingrid, Castillo, Joaquín, Comabella, Manuel, Nos, Carlos, Auger, Cristina, Tintoré, Mar, Rovira, Àlex, Montalban, Xavier, and Sastre-Garriga, Jaume

Published
2022
Full Text
View/download PDF

24. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.

Author

Calvi, Alberto, Mendelsohn, Zoe, Hamed, Weaam, Chard, Declan, Tur, Carmen, Stutters, Jon, MacManus, David, Kanber, Baris, Wheeler‐Kingshott, Claudia A. M. Gandini, Barkhof, Frederik, and Prados, Ferran

Subjects
MULTIPLE sclerosis, CONVOLUTIONAL neural networks, MAGNETIC resonance imaging, RETROSPECTIVE studies, MEDICAL screening
Abstract

Background and purpose: Newly appearing lesions in multiple sclerosis (MS) may evolve into chronically active, slowly expanding lesions (SELs), leading to sustained disability progression. The aim of this study was to evaluate the incidence of newly appearing lesions developing into SELs, and their correlation to clinical evolution and treatment. Methods: A retrospective analysis of a fingolimod trial in primary progressive MS (PPMS; INFORMS, NCT 00731692) was undertaken. Data were available from 324 patients with magnetic resonance imaging scans up to 3 years after screening. New lesions at year 1 were identified with convolutional neural networks, and SELs obtained through a deformation‐based method. Clinical disability was assessed annually by Expanded Disability Status Scale (EDSS), Nine‐Hole Peg Test, Timed 25‐Foot Walk, and Paced Auditory Serial Addition Test. Linear, logistic, and mixed‐effect models were used to assess the relationship between the Jacobian expansion in new lesions and SELs, disability scores, and treatment status. Results: One hundred seventy patients had ≥1 new lesions at year 1 and had a higher lesion count at screening compared to patients with no new lesions (median = 27 vs. 22, p = 0.007). Among the new lesions (median = 2 per patient), 37% evolved into definite or possible SELs. Higher SEL volume and count were associated with EDSS worsening and confirmed disability progression. Treated patients had lower volume and count of definite SELs (β = −0.04, 95% confidence interval [CI] = −0.07 to −0.01, p = 0.015; β = −0.36, 95% CI = −0.67 to −0.06, p = 0.019, respectively). Conclusions: Incident chronic active lesions are common in PPMS, and fingolimod treatment can reduce their number. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis.

Author

Villacieros‐Álvarez, Javier, Espejo, Carmen, Arrambide, Georgina, Castillo, Mireia, Carbonell‐Mirabent, Pere, Rodriguez, Marta, Bollo, Luca, Castilló, Joaquín, Comabella, Manuel, Galán, Ingrid, Midaglia, Luciana, Mongay‐Ochoa, Neus, Nos, Carlos, Rio, Jordi, Rodríguez‐Acevedo, Breogan, Sastre‐Garriga, Jaume, Tur, Carmen, Vidal‐Jordana, Angela, Vilaseca, Andreu, and Zabalza, Ana

Subjects
MYELIN oligodendrocyte glycoprotein, MULTIPLE sclerosis, OPTIC neuritis, MAGNETIC resonance imaging, ADULTS
Abstract

Objective: Myelin oligodendrocyte glycoprotein antibodies (MOG‐Ab) distinguish multiple sclerosis (MS) from MOG‐associated disease in most cases. However, studies analyzing MOG‐Ab at the time of a first demyelinating event suggestive of MS in adults are lacking. We aimed to (1) evaluate the prevalence of MOG‐Ab in a first demyelinating event suggestive of MS and (2) compare clinical and paraclinical features between seropositive (MOG‐Ab+) and seronegative (MOG‐Ab−) patients. Methods: Six hundred thirty adult patients with available serum samples obtained within 6 months from the first event were included. MOG‐Ab were analyzed using a live cell‐based assay. Statistical analyses included parametric and nonparametric tests, logistic regression, and survival models. Results: MOG‐Ab were positive in 17 of 630 (2.7%). Fourteen out of 17 (82.4%) MOG‐Ab+ patients presented with optic neuritis (ON) compared to 227of 613 (37.0%) MOG‐Ab− patients (p = 0.009). Cerebrospinal fluid‐restricted oligoclonal bands (CSF‐OBs) were found in 2 of 16 (12.5%) MOG‐Ab+ versus 371 of 601 (61.7%) MOG‐Ab− subjects (p < 0.001). Baseline brain magnetic resonance imaging (MRI) was normal in 9 of 17 (52.9%) MOG‐Ab+ versus 153 of 585 (26.2%) MOG‐Ab− patients (p = 0.029). Absence of CSF‐OBs and ON at onset were independently associated with MOG‐Ab positivity (odds ratio [OR] = 9.03, 95% confidence interval [CI] = 2.04–53.6, p = 0.009; and OR = 4.17, 95% CI = 1.15–19.8, p = 0.042, respectively). Of MOG‐Ab+ patients, 22.9% (95% CI = 0.0–42.7) compared to 67.6% (95% CI = 63.3–71.3) of MOG‐Ab− patients fulfilled McDonald 2017 criteria at 5 years (log‐rank p = 0.003). Interpretation: MOG‐Ab are infrequent in adults with a first demyelinating event suggestive of MS. However, based on our results, we suggest to determine these antibodies in those patients with ON and absence of CSF‐OBs, as long as the brain MRI is not suggestive of MS. ANN NEUROL 2024;95:116–128 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

Author

Carvajal, René, primary, Tur, Carmen, additional, Martínez-Gómez, Xavier, additional, Bollo, Luca, additional, Esperalba, Juliana, additional, Rodriguez, Marta, additional, Pappolla, Agustín, additional, Cobo-Calvo, Alvaro, additional, Carbonell, Pere, additional, Borras-Bemejo, Blanca, additional, Río, Jordi, additional, Castilló, Joaquín, additional, Braga, Nathane, additional, Mongay-Ochoa, Neus, additional, Rodrigo-Pendás, José Ángel, additional, Vidal-Jordana, Ángela, additional, Arrambide, Georgina, additional, Rodríguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Midaglia, Luciana, additional, Galán, Ingrid, additional, Comabella, Manuel, additional, Sastre-Garriga, Jaume, additional, Montalban, Xavier, additional, Tintoré, Mar, additional, and Otero-Romero, Susana, additional

Published
2023
Full Text
View/download PDF

27. MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis

Author

Villacieros‐Álvarez, Javier, primary, Espejo, Carmen, additional, Arrambide, Georgina, additional, Castillo, Mireia, additional, Carbonell‐Mirabent, Pere, additional, Rodriguez, Marta, additional, Bollo, Luca, additional, Castilló, Joaquín, additional, Comabella, Manuel, additional, Galán, Ingrid, additional, Midaglia, Luciana, additional, Mongay, Neus, additional, Nos, Carlos, additional, Rio, Jordi, additional, Rodríguez‐Acevedo, Breogan, additional, Sastre‐Garriga, Jaume, additional, Tur, Carmen, additional, Vidal‐Jordana, Angela, additional, Vilaseca, Andreu, additional, Zabalza, Ana, additional, Auger, Cristina, additional, Rovira, Alex, additional, Montalban, Xavier, additional, Tintoré, Mar, additional, and Cobo‐Calvo, Álvaro, additional

Published
2023
Full Text
View/download PDF

29. Association of Very Early Treatment Initiation With the Risk of Long-Term Disability in Patients With a First Demyelinating Event

Author

Cobo-Calvo, Alvaro, primary, Tur, Carmen, additional, Otero-Romero, Susana, additional, Carbonell-Mirabent, Pere, additional, Ruiz, Mariano, additional, Pappolla, Agustin, additional, Alvarez, Javier Villacieros, additional, Vidal-Jordana, Angela, additional, Arrambide, Georgina, additional, Castilló, Joaquín, additional, Galan, Ingrid, additional, Rodríguez Barranco, Marta, additional, Midaglia, Luciana soledad, additional, Nos, Carlos, additional, Rodriguez Acevedo, Breogan, additional, Zabalza de Torres, Ana, additional, Mongay, Neus, additional, Rio, Jordi, additional, Comabella, Manuel, additional, Auger, Cristina, additional, Sastre-Garriga, Jaume, additional, Rovira, Alex, additional, Tintore, Mar, additional, and Montalban, Xavier, additional

Published
2023
Full Text
View/download PDF

30. Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients

Author

Río, Jordi, Rovira, Àlex, Gasperini, Claudio, Tintoré, Mar, Prosperini, Luca, Otero-Romero, Susana, Comabella, Manuel, Vidal-Jordana, Ángela, Galán, Ingrid, Midaglia, Luciana, Rodriguez-Acevedo, Breogán, Zabalza, Ana, Castilló, Joaquim, Arrambide, Georgina, Nos, Carlos, Cobo-Calvo, Álvaro, Tur, Carmen, Auger, Cristina, Sastre-Garriga, Jaume, and Montalban, Xavier

Published
2022
Full Text
View/download PDF

34. Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course

Author

Abdel-mannan, Omar, Champsas, Dimitrios, Tur, Carmen, Lee, Vanessa, Manivannan, Sharmila, Usman, Haroon, Skippen, Alison, Desai, Ishita, Chitre, Manali, Forsyth, Rob, Kneen, Rachel, Ram, Dipak, Ramdas, Sithara, Rossor, Thomas, West, Siobhan, Wright, Sukhvir, Palace, Jacqueline, Wassmer, Evangeline, Hemingway, Cheryl, Lim, Ming J, Mankad, Kshitij, Ciccarelli, Olga, and Hacohen, Yael

Abstract

BackgroundLesion resolution is often observed in children with myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and asymptomatic lesions are less commonly reported in MOGAD than in multiple sclerosis (MS).ObjectiveWe aimed to evaluate brain MRI changes over time in paediatric MOGAD.MethodsRetrospective study in eight UK paediatric neuroscience centres. Acute brain MRI and available follow-up MRIs were reviewed. Predictors for lesion dynamic were evaluated using multivariable regression and Kaplan-Meier survival analyses were used to predict risk of relapse, disability and MOG-Ab status.Results200 children were included (MOGAD 97; MS 103). At first MRI post attack, new symptomatic and asymptomatic lesions were seen more often in MS versus MOGAD (52/103 vs 28/97; p=0.002 and 37/103 vs 11/97; p<0.001); 83% of patients with MOGAD showed at least one lesion’s resolution at first follow‐up scan, and 23% had normal MRI. Only 1 patient with MS had single lesion resolution; none had normal MRI. Disappearing lesions in MOGAD were seen in 40% after the second attack, 21% after third attack and none after the fourth attack.New lesions at first follow-up scan were associated with increased likelihood of relapse (p=0.02) and persistent MOG-Ab serostatus (p=0.0016) compared with those with no new lesions. Plasma exchange was associated with increased likelihood of lesion resolution (p=0.01). Longer time from symptom onset to steroids was associated with increased likelihood of new lesions; 50% increase at 20 days (p=0.01).ConclusionsThese striking differences in lesion dynamics between MOGAD and MS suggest greater potential to repair. Early treatment with steroids and plasma exchange is associated with reduced likelihood of new lesions.

Published
2024
Full Text
View/download PDF

35. Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course

Author

Abdel-Mannan, Omar, Champsas, Dimitrios, Tur, Carmen, Lee, Vanessa, Manivannan, Sharmila, Usman, Haroon, Skippen, Alison, Desai, Ishita, Chitre, Manali, Forsyth, Rob, Kneen, Rachel, Ram, Dipak, Ramdas, Sithara, Rossor, Thomas, West, Siobhan, Wright, Sukhvir, Palace, Jacqueline, Wassmer, Evangeline, Hemingway, Cheryl, Lim, Ming J, Mankad, Kshitij, Ciccarelli, Olga, Hacohen, Yael, Abdel-Mannan, Omar, Champsas, Dimitrios, Tur, Carmen, Lee, Vanessa, Manivannan, Sharmila, Usman, Haroon, Skippen, Alison, Desai, Ishita, Chitre, Manali, Forsyth, Rob, Kneen, Rachel, Ram, Dipak, Ramdas, Sithara, Rossor, Thomas, West, Siobhan, Wright, Sukhvir, Palace, Jacqueline, Wassmer, Evangeline, Hemingway, Cheryl, Lim, Ming J, Mankad, Kshitij, Ciccarelli, Olga, and Hacohen, Yael

Abstract

Background: Lesion resolution is often observed in children with myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and asymptomatic lesions are less commonly reported in MOGAD than in multiple sclerosis (MS). Objective: We aimed to evaluate brain MRI changes over time in paediatric MOGAD. Methods: Retrospective study in eight UK paediatric neuroscience centres. Acute brain MRI and available follow-up MRIs were reviewed. Predictors for lesion dynamic were evaluated using multivariable regression and Kaplan-Meier survival analyses were used to predict risk of relapse, disability and MOG-Ab status. Results:200 children were included (MOGAD 97; MS 103). At first MRI post-attack, new symptomatic and asymptomatic lesions were seen more often in MS vs MOGAD (52/103 vs 28/97; p=0.002 and 37/103 vs 11/97; p<0.001); 83% of MOGAD patients showed at least one lesion’s resolution at 1st follow‐up scan, and 23% had normal MRI. Only 1 MS patient had single lesion resolution; none had normal MRI. Disappearing lesions in MOGAD were seen in 40% after the 2nd attack, 21% after 3rd attack and none after the 4th attack. New lesions at 1st follow-up scan were associated with increased likelihood of relapse (p=0.02) and persistent MOG-Ab serostatus (p=0.0016) compared to those with no new lesions. Plasma exchange was associated with increased likelihood of lesion resolution (p=0.01). Longer time from symptom onset to steroids was associated with increased likelihood of new lesions; 50% increase at 20 days (p=0.01). Conclusions and Relevance: These striking differences in lesion dynamics between MOGAD and MS suggest greater potential to repair. Early treatment with steroids and plasma exchange is associated with reduced likelihood of new lesions.

Published
2023

39. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging

Author

Cortese, Rosa, primary, Prados Carrasco, Ferran, additional, Tur, Carmen, additional, Bianchi, Alessia, additional, Brownlee, Wallace, additional, De Angelis, Floriana, additional, De La Paz, Isabel, additional, Grussu, Francesco, additional, Haider, Lukas, additional, Jacob, Anu, additional, Kanber, Baris, additional, Magnollay, Lise, additional, Nicholas, Richard S., additional, Trip, Anand, additional, Yiannakas, Marios, additional, Toosy, Ahmed T., additional, Hacohen, Yael, additional, Barkhof, Frederik, additional, and Ciccarelli, Olga, additional

Published
2023
Full Text
View/download PDF

40. Genetic influences on disease course and severity, 30 years after a clinically isolated syndrome

Author

Sahi, Nitin, primary, Haider, Lukas, additional, Chung, Karen, additional, Prados Carrasco, Ferran, additional, Kanber, Baris, additional, Samson, Rebecca, additional, Thompson, Alan J, additional, Gandini Wheeler-Kingshott, Claudia A M, additional, Trip, S Anand, additional, Brownlee, Wallace, additional, Ciccarelli, Olga, additional, Barkhof, Frederik, additional, Tur, Carmen, additional, Houlden, Henry, additional, and Chard, Declan, additional

Published
2023
Full Text
View/download PDF

46. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis

Author

Tur, Carmen, primary, Carbonell-Mirabent, Pere, additional, Cobo-Calvo, Álvaro, additional, Otero-Romero, Susana, additional, Arrambide, Georgina, additional, Midaglia, Luciana, additional, Castilló, Joaquín, additional, Vidal-Jordana, Ángela, additional, Rodríguez-Acevedo, Breogán, additional, Zabalza, Ana, additional, Galán, Ingrid, additional, Nos, Carlos, additional, Salerno, Annalaura, additional, Auger, Cristina, additional, Pareto, Deborah, additional, Comabella, Manuel, additional, Río, Jordi, additional, Sastre-Garriga, Jaume, additional, Rovira, Àlex, additional, Tintoré, Mar, additional, and Montalban, Xavier, additional

Published
2022
Full Text
View/download PDF

47. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis

Author

Calvi, Alberto, primary, Clarke, Margareta A, additional, Prados, Ferran, additional, Chard, Declan, additional, Ciccarelli, Olga, additional, Alberich, Manel, additional, Pareto, Deborah, additional, Rodríguez Barranco, Marta, additional, Sastre-Garriga, Jaume, additional, Tur, Carmen, additional, Rovira, Alex, additional, and Barkhof, Frederik, additional

Published
2022
Full Text
View/download PDF

49. Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis

Author

Otero-Romero, Susana, Carbonell-Mirabent, Pere, Midaglia, Luciana, Zuluaga, María, Galan, Ingrid, Cobo-Calvo, Álvaro, Río, Jordi, Arrambide, Georgina, Vidal-Jordana, Angela, Castillo, Joaquín, Rodríguez Acevedo, Breogán, Comabella, Manuel, Rodríguez, Marta, Tur, Carmen, Auger, Cristina, Rovira, Alex, Sastre-Garriga, Jaume, Montalban, Xavier, Tintoré, Mar, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Otero-Romero S] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Servei de Neurologia-Neuroimmunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Carbonell-Mirabent P, Midaglia L, Zuluaga M, Galán I, Cobo-Calvo A, Rio J, Arrambide G, Vidal-Jordana A, Castillo J, Rodríguez-Acevedo B, Comabella M, Rodríguez M, Tur C, Sastre-Garriga J, Montalban X, Tintoré M] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Servei de Neurologia-Neuroimmunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Auger C, Rovira A] Secció de Neuroradiologia, Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, medicine.medical_specialty, Multiple Sclerosis, acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::sustancias para el control de la reproducción::anticonceptivos::anticonceptivos femeninos::anticonceptivos orales [COMPUESTOS QUÍMICOS Y DROGAS], Esclerosi múltiple, Multiple sclerosis, Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Reproductive Control Agents::Contraceptive Agents::Contraceptive Agents, Female::Contraceptives, Oral [CHEMICALS AND DRUGS], Nervous System Diseases::Demyelinating Diseases [DISEASES], Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, enfermedades del sistema nervioso::enfermedades desmielinizantes [ENFERMEDADES], Second relapse, Disability, Expanded Disability Status Scale, Clinically isolated syndrome, Oral contraceptives, Mielina - Malalties, Contraceptius orals, Proportional hazards model, business.industry, Hazard ratio, Confounding, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], Confidence interval, Cross-Sectional Studies, Neurology, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Disease Progression, Female, Neurology (clinical), Cohort study, business, Contraceptives, Oral, Demyelinating Diseases
Abstract

Cohort study; Oral contraceptives; Second relapse Estudio de cohorte; Anticonceptivos orales; Segunda recaída Estudi de cohorts; Anticonceptius orals; Segona recaiguda Objective: To evaluate whether oral contraceptive (OC) use is associated with the risk of a second attack and disability accrual in women with a clinically isolated syndrome (CIS) and early multiple sclerosis (MS). Methods: Reproductive information from women included in the Barcelona CIS prospective cohort was collected through a self-reported cross-sectional survey. We examined the relationship of OC exposure with the risk of a second attack and confirmed Expanded Disability Status Scale of 3.0 using multivariate Cox regression models, adjusted by age, topography of CIS, oligoclonal bands, baseline brain T2 lesions, body size at menarche, smoking, and disease-modifying treatment (DMT). OC and DMT exposures were considered as time-varying variables. Findings were confirmed with sensitivity analyses using propensity score models. Results: A total of 495 women were included, 389 (78.6%) referred to ever use OC and 341 (68.9%) started OC before the CIS. Exposure to OC was not associated with a second attack (adjusted hazard ratio (aHR) = 0.73, 95% confidence interval (CI) = 0.33–1.61) or disability accrual (aHR = 0.81, 95% CI = 0.17–3.76). Sensitivity analyses confirmed these results. Conclusion: OC use does not modify the risk of second attack or disability accrual in patients with CIS and early MS, once considered as a time-dependent exposure and adjusted by other potential confounders. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by FIS PI15/0070 from Ministry of Economy and Competitiveness of Spain.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results